GoAI
Get started
Arcutis Biotherapeutics, Inc. logo

Arcutis Biotherapeutics, Inc.

ARQT

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$25.08

−$0.27 · -1.07%

Aug 21, 4:00 PM ET

ARQT company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

79

Undervalued

Momentum

59

Neutral

Sentiment

55

Mixed

Risk resilience

57

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Industry
Biotechnology
Sector
Healthcare
Headquarters
US

Market position

Day range

Current $25.08

52-week range

Current $25.08

Open
$25.46
Previous close
$25.35
Volume
2.16M
Market cap
3.14B USD
50-day average
$26.7118
-6.11% below average
200-day average
$25.6066
-2.06% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
3.66B USD
P/E (TTM)
113.59×
P/B (TTM)
14.84×
P/S (TTM)
6.76×
EV / EBITDA
1,475.09×
Earnings yield
-0.44%
Free cash flow yield
-0.17%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
91.14%
Operating margin
7.38%
Net margin
6.15%
Return on equity
-8.52%
Return on assets
-3.73%
Return on invested capital
-4.02%

Financial health

Debt / equity
0.52×
Current ratio
3.17×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends946%-2471%-5887%-9304%Gross margin, FY2022: 79.54%Gross margin, FY2023: 91.63%Gross margin, FY2024: 90.27%Gross margin, FY2025: 90.24%Operating margin, FY2022: -8183.04%Operating margin, FY2023: -404.49%Operating margin, FY2024: -65.33%Operating margin, FY2025: -3.25%Net margin, FY2022: -8449.76%Net margin, FY2023: -439.79%Net margin, FY2024: -71.25%Net margin, FY2025: -4.29%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2022 79.54%. Gross margin FY2023 91.63%. Gross margin FY2024 90.27%. Gross margin FY2025 90.24%. Operating margin FY2022 -8183.04%. Operating margin FY2023 -404.49%. Operating margin FY2024 -65.33%. Operating margin FY2025 -3.25%. Net margin FY2022 -8449.76%. Net margin FY2023 -439.79%. Net margin FY2024 -71.25%. Net margin FY2025 -4.29%.

Income trends

Revenue

376.07M USD+91.34%

Operating income

−12.23M USD+90.48%

Net income

−16.14M USD+88.47%
Income trends across reported periods444.83M USD169.81M USD−105.2M USD−380.21M USDRevenue, FY2022: 3.69M USDRevenue, FY2023: 59.61M USDRevenue, FY2024: 196.54M USDRevenue, FY2025: 376.07M USDOperating income, FY2021: −206.53M USDOperating income, FY2022: −301.63M USDOperating income, FY2023: −241.1M USDOperating income, FY2024: −128.4M USDOperating income, FY2025: −12.23M USDNet income, FY2021: −206.36M USDNet income, FY2022: −311.46M USDNet income, FY2023: −262.14M USDNet income, FY2024: −140.04M USDNet income, FY2025: −16.14M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2022 3.69M USD. Revenue FY2023 59.61M USD. Revenue FY2024 196.54M USD. Revenue FY2025 376.07M USD. Operating income FY2021 −206.53M USD. Operating income FY2022 −301.63M USD. Operating income FY2023 −241.1M USD. Operating income FY2024 −128.4M USD. Operating income FY2025 −12.23M USD. Net income FY2021 −206.36M USD. Net income FY2022 −311.46M USD. Net income FY2023 −262.14M USD. Net income FY2024 −140.04M USD. Net income FY2025 −16.14M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue376.07M USD196.54M USD59.61M USD3.69M USD—
Cost of goods sold36.7M USD19.13M USD4.99M USD754K USD763K USD
Gross profit339.38M USD177.41M USD54.62M USD2.93M USD−763K USD
Research and development77.05M USD76.42M USD110.58M USD182.44M USD145.56M USD
Selling, general, and administrative274.55M USD229.39M USD185.15M USD122.12M USD60.97M USD
Operating expenses351.6M USD305.81M USD295.72M USD304.56M USD205.77M USD
Interest income————173K USD
Interest expense12.08M USD27.17M USD29.71M USD15.65M USD—
Depreciation and amortization5.37M USD2.6M USD1.88M USD1.25M USD763K USD
Operating income−12.23M USD−128.4M USD−241.1M USD−301.63M USD−206.53M USD
Net income−16.14M USD−140.04M USD−262.14M USD−311.46M USD−206.36M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
82%
9 beats, 2 misses, 0 met estimates
Average EPS surprise
+37.57%
11 comparable reports
Latest EPS result
0.11
Estimate 0.06 · Beat by 99.71%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.210.03-0.14-0.32Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 25, 2025: actual -0.09, estimate -0.28, surprise +67.86%, Beat. Q2 2025, reported May 6, 2025: actual -0.2, estimate -0.21, surprise +4.76%, Beat. Q3 2025, reported Aug 6, 2025: actual -0.13, estimate -0.18, surprise +27.78%, Beat. Q4 2025, reported Oct 28, 2025: actual 0.06, estimate -0.1, surprise +160.00%, Beat. Q1 2026, reported Feb 25, 2026: actual 0.13, estimate 0.03, surprise +333.33%, Beat. Q2 2026, reported May 6, 2026: actual -0.09, estimate -0.02, surprise -350.00%, Miss. Q3 2026, reported Aug 5, 2026: actual 0.11, estimate 0.055, surprise +99.71%, Beat. Q4 2026, reported Oct 27, 2026: actual —, estimate 0.17, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates147.46M116.33M85.2M54.08MQ1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 25, 2025: actual 71.36M USD, estimate 60.52M USD, surprise +17.92%, Beat. Q2 2025, reported May 6, 2025: actual 65.85M USD, estimate 72.7M USD, surprise -9.43%, Miss. Q3 2025, reported Aug 6, 2025: actual 81.5M USD, estimate 80.63M USD, surprise +1.09%, Beat. Q4 2025, reported Oct 28, 2025: actual 99.22M USD, estimate 110.79M USD, surprise -10.45%, Miss. Q1 2026, reported Feb 25, 2026: actual 129.5M USD, estimate 113.06M USD, surprise +14.55%, Beat. Q2 2026, reported May 6, 2026: actual 105.4M USD, estimate 103.68M USD, surprise +1.66%, Beat. Q3 2026, reported Aug 5, 2026: actual 129.86M USD, estimate 118.85M USD, surprise +9.26%, Beat. Q4 2026, reported Oct 27, 2026: actual —, estimate 141.02M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$36.67

46.21% upside
Past 12 months12-month forecast

Price history unavailable

High $38.00Average $36.67Low $34.00

ARQT news

globenewswire.com

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology,…

Read source
fool.com

Arcutis President and CEO Todd Watanabe Sells 4,375 Shares for $114,275 as Q2 Results Demonstrate Profitability

Watanabe's sale was non-discretionary, executed to cover tax withholding on vesting RSUs. Watanabe retains 950,000+ shares valued at $24.65 million, signaling continued confidence.

Read source
seekingalpha.com

Arcutis Biotherapeutics, Inc. (ARQT) Q2 2026 Earnings Call Transcript

Arcutis Biotherapeutics, Inc. (ARQT) Q2 2026 Earnings Call Transcript

Read source
zacks.com

Arcutis Biotherapeutics, Inc. (ARQT) Q2 Earnings and Revenues Surpass Estimates

Arcutis Biotherapeutics, Inc. (ARQT) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to a loss of $0.13 per share a year ago.

Read source
marketbeat.com

Arcutis Biotherapeutics Q2 Earnings Call Highlights

Arcutis Biotherapeutics NASDAQ: ARQT reported second-quarter 2026 net product revenue of $129.9 million, up 59% from the prior-year period and 23% sequentially, as demand for its ZORYVE topical treatments continued to…

Read source
globenewswire.com

Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update

Continued strong ZORYVE® (roflumilast) net product revenue growth, with Q2 revenues of $129.9 million, +59% versus Q2 of 2025, and +23% versus Q1 of 2026, driven primarily by strong demand growth Company raising 2026…

Read source

ARQT peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding ARQT

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
96.17M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
77.33M
Weight
0.68%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$165.73+1.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
73.54M
Weight
0.09%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
35.19M
Weight
0.04%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
26.91M
Weight
0.18%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
20.96M
Weight
0.20%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
17.25M
Weight
0.10%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
13.78M
Weight
0.06%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%

Continue in GoAI

Research ARQT

research.disclaimer